Review Article
Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants
Table 1
Summary of pharmacokinetic properties of nonvitamin K antagonist oral anticoagulants (NOACs) [
22–
25].
| | Dabigatran | Rivaroxaban | Apixaban |
| Target | Factor lla | Factor Xa | Factor Xa | Prodrug | Yes | No | No | Tmax (h) | 1.5–3.0 | 2.0–4.0 | 3.0–4.0 | Distribution volume (L) | 60–70 | ±50 | 23 | Half-life (h) | 11: healthy individuals 12-13: elderly | 5–9: healthy individuals 11–13: elderly | 8–15: healthy individuals | Bioavailability | 3–7% pH sensitive | 80–100%: 10 mg 66%: 15–20 mg under fasting conditions | ±50% | Protein binding | 35% | >90% | 87% | Metabolism | Conjugation | CYP-dependent and independent mechanism | CYP-dependent mechanism | Active metabolites | Yes glucuronide conjugates | No | No |
Elimination |
80% renal |
33% unchanged via the kidney |
25% renal |
20% bile (glucuronide conjugation) | 66% metabolized in the liver into inactive metabolites then eliminated via the kidney or the colon in an approximate 50% ratio | 75% through the liver while the residue is excreted by the hepatobiliary route in the feces | Effects of food | Tmax delayed; Cmax and AUC unchanged | Tmax delayed; Cmax and AUC increased (76% and 30–40%, respectively) | Tmax delayed; Cmax and AUC unchanged | CYP substrate | No | CYP3A4, CYP2J2 | CYP3A4 | P-gp substrate | DE: yes | Yes | Yes |
|
|